Arisz Acquisition Corp.
We intend to search globally with a focus on targets in the healthcare industry.
Our sponsor is an affiliate of M.S.Q. Ventures Inc (MSQ), a research-driven advisory firm with deep domain expertise in life sciences.
Our primary focus will be on the life sciences industry. We believe the life sciences industry represents an enormous and growing target market with a large number of potential target acquisition opportunities. The life sciences industry includes, but is not limited to, companies operating in the research, development and manufacturing of pharmaceuticals, biotechnology-based food and medicines, medical devices, biomedical technology, biophysics, neuroscience, cell biology or cosmeceuticals.
We believe that there is tremendous investor demand for initial public offerings in the life-sciences sector and that the coronavirus, or COVID-19, pandemic has led to a renewed appreciation of the critical contributions the sector makes to society, which in turn will continue to support investor demand.
(Note: Arisz Acquisition Corp. priced its SPAC IPO on Nov. 18, 2021, in sync with the terms in its prospectus: 6 million units at $10 each to raise $60 million.)
|Address||199 Water St, 31st Floor New York, NY 10038|
|View Prospectus:||Arisz Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$60.0 mil|
|Manager / Joint Managers||Chardan|
|Expected To Trade:||11/18/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|